Abstracts tagged "T cells"

Abstract Number: 820 • 2015 ACR/ARHP Annual Meeting
Peripheral Blood and Disease Features Associated with Complement Components C3 and C4 in SLE
Mikhail Olferiev, David Fernandez, Leila Khalili, Dina Greenman, Mary K. Crow and Kyriakos A. Kirou, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY
Background/Purpose: Decreases in peripheral blood levels of complement components of C3 and C4 are associated with SLE and often indicate a lupus flare. The aim…
Abstract Number: 1606 • 2015 ACR/ARHP Annual Meeting
Telomere Damage in Rheumatoid Arthritis
Yinyin Li¹, Jihang Ju¹, Thomas M. Bush², Mark C. Genovese³, Jorg Goronzy¹ and Cornelia M. Weyand⁴, ¹Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Medicine/Rheumatology, Santa Clara Valley Medical Center, San Jose, CA, ³Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Production of anti-CCP autoantibodies, the hallmark of rheumatoid arthritis (RA), is dependent on T cell help, positioning T cells into a pinnacle position in…
Abstract Number: 1942 • 2015 ACR/ARHP Annual Meeting
B Cell Depletion By Rituximab in Lymphocyte Subpopulations from Peripheral Blood in Patients with Rheumatoid Arthritis
Leticia Merino-Meléndez¹, Jorge López-López², Irene Llorente¹, Santos Castañeda³, Federico Herrera², Teresa Velasco⁴, Lorena Vega⁵, Francisco Rodriguez⁵, Jose María Alvaro-Gracia³, Rosario Garcia-Vicuña⁶, Cecilia Muñoz-Calleja² and Isidoro Gonzalez-Alvaro⁷, ¹Rheumatology, H.U. La Princesa, Madrid, Spain, ²Immunology, Hospital Universitario de La Princesa, Madrid, Spain, ³Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁴Rheumatology, H.U La Princesa, Madrid, Spain, ⁵H.U. La Princesa, Madrid, Spain, ⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁷Hospital Univ. de La Princesa, IIS Princesa, Madrid, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease that leads to inflammation of the joints and other tissues. Rituximab (Rtx) is a therapeutic monoclonal antibody…
Abstract Number: 3021 • 2015 ACR/ARHP Annual Meeting
The Adaptor Protein Crkii Regulates Rap1 Activation in the Immunological Synapse
Adam Mor¹ and Inbar Alfaguter², ¹Rheumatology and Pathology, NYU Langone Medical Center, New York, NY, ²NYU, New York, NY
Background/Purpose: Crk proteins are a family of adaptors that play an important role in regulating multiple T cell functions. The two main Crk isoforms are…
Abstract Number: 2738 • 2014 ACR/ARHP Annual Meeting
Shk-186, a Kv1.3 channel inhibitor That Targets Effector Memory T Cells: Safety and Tolerability in Humans and Its Evaluation in a Model of Rapidly Progressive Glomerulonephritis
Ernesto J. Muñoz-Elías¹, Kayla Norton¹, John B. Grigg¹, Liz Bromley¹, David W. Peckham¹, Eric J. Tarcha¹, Jared Odegard², James Qin², Megan Yuasa³, Anne Stevens⁴, Wayel H. Abdulahad⁵, Galina Schmunk⁶, K. George Chandy⁶ and Shawn P. Iadonato¹, ¹Kineta Inc., Seattle, WA, ²Benaroya Research Institute at Virginia Mason, Seattle, WA, ³Seattle Children's Res Institute, Seattle Children's Research Institute, Seattle, WA, ⁴Seattle Children's Res Inst, Seattle Children's Hospital, Seattle, WA, ⁵Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁶Department of Physiology, Biophysics, and Surgery, UC Irvine, Irvine, CA
Background/Purpose: The voltage-gated potassium channel Kv1.3 is a novel target for the treatment of autoimmune disorders including psoriatic and rheumatic diseases. ShK-186 is an exquisitely specific,…
Abstract Number: 1899 • 2014 ACR/ARHP Annual Meeting
Blockade of Interleukin-33 Signaling Prevents Death in a Mouse Model of Familial Hemophagocytic Lymphohistiocytosis
Julia Rood¹, Portia Kreiger², Erietta Stelekati¹, E. John Wherry¹ and Edward M. Behrens³, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Pathology, Alfred I. duPont Hospital for Children, Wilmington, DE, ³Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose Cytokine storm syndromes, such as macrophage activation syndrome and familial hemophagocytic lymphohistiocytosis (FHL), represent important causes of mortality in pediatric rheumatology. Studies of a…
Abstract Number: 1642 • 2014 ACR/ARHP Annual Meeting
A Prospective Study of Vitamin D Effects on T Cells Phenotype in Patients with Systemic Lupus Erythematosus Treated with Different Regimens of Supplementation for Two Years
Silvia Piantoni, Laura Andreoli, Alessandra Zanola, Francesca Dall'Ara, Mirko Scarsi and Angela Tincani, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose Vitamin D (VD) receptor is constitutively expressed on the membrane of multiple cells, including lymphocytes. Recent studies highlight that VD may have an action…
Abstract Number: 645 • 2014 ACR/ARHP Annual Meeting
The Combination of Metformin and 2-Deoxy-D-Glucose Normalizes CD4 T Cell Metabolism and Functions, and Reverse Disease in Murine Models of Lupus
Laurence Morel¹, Yiming Yin², Seung-Chul Choi², Eric S. Sobel³ and Byron Croker², ¹Pathology/Immunology/Lab Medical, University of Florida, Gainesville, FL, ²University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL
Background/Purpose: Autoreactive CD4 T cells are key effectors in Systemic Lupus Erythematosus (SLE). Cell metabolism is an important checkpoint for T cell activationand differentiation. Both…
Abstract Number: 2742 • 2014 ACR/ARHP Annual Meeting
Polymorphisms in the Slam Family of Molecules Play a Role in the Development and Function of Invariant Natural Killer T Cells in New Zealand Black Mice
Yuriy Baglaenko¹, Kieran Manion¹, Nan-Hua Chang² and Joan E. Wither³, ¹Immunology, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: The family of signaling lymphocyte activating molecules (SLAM) have been shown to play a key role in the development of autoimmunity in spontaneous and…
Abstract Number: 1816 • 2014 ACR/ARHP Annual Meeting
Toll-like Receptor 4-Induced Interleukin-1 Defines the Intestinal Microbiome and Mucosal Immune Response in Arthritis-Prone IL-1 Receptor Antagonist Deficient Mice
Tom Ederveen¹, Rebecca Rogier², Jos Boekhorst¹, Harm Wopereis³, Johan Garssen³, Sacha van Hijum¹, Fons A.J. van de Loo², Marije I. Koenders², Wim B. van den Berg² and Shahla Abdollahi-Roodsaz⁴, ¹Centre for Molecular Bioinformatics Nijmegen (CMBI), Radboud university medical center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Danone Research, Wageningen, Netherlands, ⁴Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose Interleukin-1 (IL-1) plays a pivotal role in inflammation and autoimmunity. Mice deficient in the IL-1 receptor antagonist (IL-1Ra-/-) spontaneously develop a T cell-driven autoimmune…
Abstract Number: 1604 • 2014 ACR/ARHP Annual Meeting
IFN-γ (Th₁), IL4 (Th₂), and IL5 (Th₂) Are Elevated in Pre-Clinical SLE and Predict Transition to Classified Disease Prior to Appearance of Autoantibodies or Clinical Criteria
Rufei Lu^1,2, Melissa E. Munroe³, Joel M. Guthridge², Krista M. Bean², Dustin Fife², John B. Harley⁴, Judith A. James⁵ and Michael P. Keith⁶, ¹Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose Systemic Lupus Erythematosus (SLE) is a clinically diverse autoimmune disease that often begins with a pre-disease period of autoantibody production and symptom accrual.…
Abstract Number: 642 • 2014 ACR/ARHP Annual Meeting
Treatment with a Glycolipid Ameliorates Lupus Dermatitis and Expands Skin ãä T Cells That Promote the Migration of Langerhans Dendritic Cells
Ram Raj Singh^1,2,3, Anna Eriksson¹, Darshan Randhawa¹ and Miguel-Angel Gutierrez¹, ¹Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, UCLA, Los Angeles, CA, ²Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, ³Interdepartmental Program in Molecular Toxicology, UCLA, Los Angeles, CA
Background/Purpose: Self antigens are taken from tissues to local lymphoid organs to acquire ability to avoid self-reactivity. This important immune function is accomplished by dendritic…
Abstract Number: 2730 • 2014 ACR/ARHP Annual Meeting
FcγRIIIa Ligation in Human Peripheral CD4⁺ T-Cells Generate T_H17 like Population
Anil K. Chauhan¹, Terry Moore² and Chen Chen³, ¹Rheumatology, Saint Louis University, St. Louis, MO, ²Rheumatology/Immunology, St Louis University, Saint Louis, MO, ³Rheumatology/Internal Medicine, Saint Louis University, St. Louis, MO
Background/Purpose: Cytokines produced during TH17 response, IL-17A and IL17F drive inflammation and autoimmunity. They also act as a bridge between adaptive and innate immunity. Immune…
Abstract Number: 1799 • 2014 ACR/ARHP Annual Meeting
Elevated Indoleamine-2,3-Dioxygenase (IDO) Activity and Kynurinene-3-Monooxygenase (KMO) Expression in Interferon Positive Primary Sjogrens Syndrome Patients Is Associated with Increased CD25^hiFoxP3⁺regulatory Tcells: A Skew Towards Neurotoxicity or an Attempt to Rescue?
Naomi I Maria¹, Cornelia G. van Helden-Meeuwsen¹, Zana Brkic¹, Sandra M.J. Paulissen^1,2, Virgil A. Dalm¹, Paul L. van Daele¹, P. Martin van Hagen¹, Sinead M. Gibney^1,3, Andrew Harkin³, Hemmo A. Drexhage¹, Erik Lubberts^1,2 and Marjan A. Versnel¹, ¹Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ²Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands, ³Trinity College Institute of Neuroscience, Neuropsychopharmacology, Dublin, Ireland
Background/Purpose: A role for indoleamine-2,3-dioxygenase (IDO) in suppression of effector T-cell function and promotion of regulatory T-cell (Treg) differentiation has been described. IDO - the…
Abstract Number: 1602 • 2014 ACR/ARHP Annual Meeting
Th9 Cells in Inflammatory Cascades of Autoimmune Arthritis
Siba Raychaudhuri¹, Anupam Mitra², Ananya Datta Mitra³, Christine Abria⁴ and Smriti K. Raychaudhuri³, ¹Med/Rheumatology, Univ California Davis/VA Sac, Davis, CA, ²Dermatology, VA Sacramento Medical Center, Mather, CA, ³Rheumatology, VA Sacramento Medical Center, Mather, CA, ⁴Research, VA Sacramento Medical Center, Mather, CA
Background/Purpose: Interleukin (IL)-9, a member of IL-2 cytokine family was recently attributed to a novel CD4 T cell subset termed Th9 cells in the murine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.